Professor Cezary Cybulski, habilitated doctor of medical sciences, is an expert in the field of clinical genetics of cancer. He has been employed at the Pomeranian Medical University in Szczecin in the Department of Genetics and Pathomorphology since 2001.

Achievements:

• author of over 350 publications in peer-reviewed journals
• number of citations of works – 22 thousand
• Hirsch Index – 72 (Google Scholar)
• supervisor of 10 doctorates
• creator of the Polish VHL Family Register, maintained since 1997
• discoverer of new genes for breast cancer RECQL (Cybulski C et al. Nat Genet 2015) and ATRIP (Cybulski C et al. American Journal of Human Genetics 2023)
• discoverer of the NBN gene as a high-risk gene for prostate cancer (Cybulski et al., Cancer Research 2004).
• discoverer of founder mutations in the CHEK2 gene (Cybulski et al., AJHG 2004) and PALB2 in Poland (Cybulski et al. Lancet Oncology 2015).
• described the spectrum of gene mutations predisposing to breast and prostate cancer in Poland using whole-exome sequencing (articles in IJC in 2019 and 2020)
• author of over 10 granted patents, including 2 international ones
• author of diagnostic tests for quick and sensitive diagnosis of mutations in the VHL, NBN, PALB2 and CHEK2 genes
  related to susceptibility to cancer in Poland
• author of chapters in the textbook “Clinical Genetics of Cancer” and co-author of 5 chapters in Polish textbooks.
• participant of the international PRACTICAL and IMPACT studies
• present in the list of TOP 2% of the best scientists in the world

Important roles played:

• clinical genetics consultant in the West Pomeranian Voivodeship
• editor of the international journal “Hereditary Cancer in Clinical Practice”
• member of the Committee of Human Genetics and Molecular Pathology of the Polish Academy of Sciences from 2012 to 2023.
• member of the Management Board of the Polish Society of Human Genetics from 2014 to 2018.
• member of the Polish Society of Human Genetics and the Polish Pediatric Society.
• expert of the National Science Center in 2013, 2014.

In the “Wellysa” application, he will assess the risk of cancer depending on pedigree and clinical data and the occurrence of mutations, and will provide individual consultations to application users.